FDAsafety guidance72% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to TQB Biopharma.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Pancreatic Ductal Adenocarcinoma
- Sub-indication
- General
Related signal: Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated